A Phase 3 interventional study of NGR-hTNF plus Best Investigator's Choice (BIC) and Placebo plus Best Investigator's Choice (BIC) in Malignant Pleural Mesothelioma, sponsored by AGC Biologics S.p.A.. Completed at 49 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-17.
Sponsored by AGC Biologics S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Mesothelioma, Malignant with a site in Italy — 7 open to participants now, 12 under way, 2 of them phase 3. Mesothelioma, Malignant · Italy.
Among the 45 studies in Mesothelioma, Malignant with a site in Italy, this one is the 3rd largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2010, is one of 7 in phase 3, and was the 8th registered.
339 studies on the registry are indexed under Mesothelioma, Malignant; 63 are open to participants now.
Browse Mesothelioma, Malignant studies →7 of the 45 studies in Mesothelioma, Malignant with a site in Italy are open now. Recruiting first, the newest first:
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages 18+
Centro di Riferimento Oncologico - Aviano · Sites in Italy
Ages 18+
NovoCure Ltd. · Sites in Italy, Germany, Netherlands
Ages 18+
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18+ · Healthy volunteers
Azienda Ospedaliero-Universitaria di Parma · Sites in Italy
Ages 1+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 54 Mesothelioma, Malignant studies recruiting now, 42 (78%) set no upper age limit and 5 (9%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 21 · Phase 3 8
First in 1997; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 400 is above the median of 39 across 271 interventional studies indexed under Mesothelioma, Malignant.
Median enrollment 88 across the 33 interventional studies, 138 across the 12 observational. Of the 27 that completed or were terminated, 6 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 45 have an industry lead sponsor. The 10 most frequent:
AGC Biologics S.p.A. is the lead sponsor of 19 studies on the registry; none are open to participants now.
AGC Biologics S.p.A. has 3 studies filed under Mesothelioma, Malignant — fewer than ten, so there is no comparison to draw.
4 of the studies in Mesothelioma, Malignant with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04996017Phase 3Gruppo Oncologico Italiano di Ricerca ClinicaAtezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) | 2027-07-30 |
| NCT03546426Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSPembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies | 2027-01 |
| NCT07403630Azienda Ospedaliero-Universitaria di ParmaINTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) | 2027-02 |
| NCT06637345Centro di Riferimento Oncologico - AvianoIdentification of Prognostic and Predictive Biomarkers of Toxicity in Patients With Malignant Pleural Mesothelioma and Treated With High Doses of Radiotherapy (MESORTIBO) | 2027-03-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Mesothelioma, Malignant with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
Currently, there are no regulatory-approved or widely accepted treatment options for patients failing a standard pemetrexed-based chemotherapy regimen.
For this reason, the best supportive care (BSC) alone might be considered as a standard reference for a randomized phase III trial in this setting.
However, single-agent chemotherapeutic agents (such as doxorubicin,gemcitabine, or vinorelbine) with a well-documented safety profile and antitumor activity are also used in clinical practice.
Therefore, the best investigator's choice (BIC) between either best supportive care alone or combined with a few selected single-agent chemotherapy (including doxorubicin, gemcitabine, or vinorelbine) might be considered as an acceptable reference arm as well in this setting.
The current phase III study aims to show a superior efficacy in terms of overall survival duration of NGR-hTNF 0.8 µg/mq weekly plus BIC versus placebo plus BIC in advanced MPM patients progressing after a standard pemetrexed-based chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate baseline bone marrow, hepatic and renal function, defined as follows:
Patients may have had prior therapy providing the following conditions are met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NGR-hTNF plus Best Investigator's Choice
Drug: NGR-hTNF plus Best Investigator's Choice (BIC)
Placebo plus Best Investigator's Choice
Drug: Placebo plus Best Investigator's Choice (BIC)
* NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs. * Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis * Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination: 1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
Also known as: NGR-hTNF+BIC
* Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs. * Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis * Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination: 1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
Also known as: Placebo+BIC
Overall Survival (OS)
Defined as the time from the date of randomization until the date of death due to any cause or the last date the patient was known to be alive
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, wichever came first, assesed up to 48 months
Progression-Free Survival (PFS)
Defined as the time from the date of randomization until disease progression, or deathdue to any couse or the last patient was konwn to be alive. Progression is defined usind Response Evaluation Criteria In Solid Tumors Criteria (Recist v1.1), as a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition torelative increase of 20% the sum must also demonstrate an absolute increase of at least 5 mm. In addition the appearance of one or more new lesions was also considered progression
Time frame: From the date of randomization until the date of first documented progression or date of death from any cause, wichever came first, assessed up to 48 months
Disease Control Rate (DCR)
Disease control rate (DCR), defined as the percentage of patients who have a best-response rating of complete or partial response or stable disease, according to MPM-modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Time frame: Assessed every 6-12 weeks, up to 100 weeks
Number of Partecipants With Disease Control for ≥ 6 Months
Measured from the date of randomization until disease progression, or death due to any cause
Time frame: Assessed every 6-12 weeks, up to 100 weeks
Number of Partecipants With Adverse Events
All adverse events will be recorded according to CTC version 4.02 (CTC reference: http://ctep.cancer.gov/reporting/ctc.html) on the case report forms (CRFs); the investigator will decide if those events are drug related and his decision will be recorded on the forms for all adverse events.
Time frame: Assessed every 6-12 weeks, up to 100 weeks
Time to LCSS Symptomatic Progression
Quality of life (QoL) assessment was performed by using a questionnaire according to The Lung Cancer Symptom Scale (LCSS) . The LCSS is designed as a disease and site-specific measure of QoL particularly for use in clinical trials. It evaluates six major symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) associated with lung malignancies and their effect on overall symptomatic distress, functional activities, and global QoL. Within this trial the questionnaire according to LCSS was only recorded by the patient (patient's scale). QoL assessment was performed by using a questionnaire according to LCSS, which consists of nine 100-mm visual analog scales, with scores reported from 0 to 100 (0 representing the best score). The LCSS subscore is the average symptom burden index computed as the mean score for all six major symptoms. Symptomatic progression was defined as a worsening in the average symptom burden index by 25%.
Time frame: from the date of randomization to the date of the LCSS assessment on which symptomatic progression was identified, assessed on cycle 2, cycle 4 and cycle 6 (each cycle lasted 21 days)
Evaluation of Medical Care Utilization in the Two Treatment Arms
Medical resource use data collected will be used in health economic analyses where it may be combined with other data from other sources such as cost data or other clinical parameters.
Time frame: Assessed every 6-12 weeks, up to 100 weeks
Study Period: April 12th, 2010(First enrolment); January 21st, 2013 (date of last enrolment); April 29th, 2014 (cut-off date). 15 clinical sites in Italy, 10 in UK, 7 in USA, 4 in Belgium, 2 in Canada, 2 in Netherland, 2 in Poland, 1 in Egypt, 1 in Ireland;1 in Sweden
| Milestone | A: NGR-hTNF + BIC | B: Placebo+BIC |
|---|---|---|
| Started | 200 | 200 |
| Completed | 193 | 193 |
| Not completed | 7 | 7 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Death | 3 | 2 |
| Withdrew: Withdrawal by subject | 3 | 5 |
Defined as the time from the date of randomization until the date of death due to any cause or the last date the patient was known to be alive
| months | A: NGR-hTNF + BIC | B: Placebo+BIC |
|---|---|---|
| Overall Survival (OS) | 8.5 (7.2 to 9.9) | 8.0 (6.6 to 8.9) |
Defined as the time from the date of randomization until disease progression, or deathdue to any couse or the last patient was konwn to be alive. Progression is defined usind Response Evaluation Criteria In Solid Tumors Criteria (Recist v1.1), as a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition torelative increase of 20% the sum must also demonstrate an absolute increase of at least 5 mm. In addition the appearance of one or more new lesions was also considered progression
| months | A: NGR-hTNF + BIC | B: Placebo+BIC |
|---|---|---|
| Progression-Free Survival (PFS) | 3.4 (2.7 to 4.1) | 3.0 (2.3 to 3.7) |
Disease control rate (DCR), defined as the percentage of patients who have a best-response rating of complete or partial response or stable disease, according to MPM-modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria
| Participants | A: NGR-hTNF + BIC | B: Placebo+BIC |
|---|---|---|
| Disease control rate (DCR) | 114 | 109 |
| Complete or partial response (CR o PR) | 3 | 6 |
| Stable disease (SD) | 111 | 103 |
| Progressive disease (PD) | 51 | 71 |
| Nonassessable (NA) | 35 | 20 |
Measured from the date of randomization until disease progression, or death due to any cause
| Participants | A: NGR-hTNF + BIC | B: Placebo+BIC |
|---|---|---|
| Number of Partecipants With Disease Control for ≥ 6 Months | 84 | 76 |
All adverse events will be recorded according to CTC version 4.02 (CTC reference: http://ctep.cancer.gov/reporting/ctc.html) on the case report forms (CRFs); the investigator will decide if those events are drug related and his decision will be recorded on the forms for all adverse events.
| participants | A: NGR-hTNF + BIC | B: Placebo+BIC |
|---|---|---|
| Study-emergent AEs of any grade | 191 | 185 |
| Study-emergent AEs of grade 3 | 102 | 86 |
| Study-emergent AEs of grade 4 | 22 | 19 |
| Study-emergent AEs of grade 5 | 12 | 13 |
| Treatment-related AEs of grade 5 | 0 | 0 |
| Treatment discontinuation due to AEs | 31 | 24 |
Quality of life (QoL) assessment was performed by using a questionnaire according to The Lung Cancer Symptom Scale (LCSS) . The LCSS is designed as a disease and site-specific measure of QoL particularly for use in clinical trials. It evaluates six major symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) associated with lung malignancies and their effect on overall symptomatic distress, functional activities, and global QoL. Within this trial the questionnaire according to LCSS was only recorded by the patient (patient's scale). QoL assessment was performed by using a questionnaire according to LCSS, which consists of nine 100-mm visual analog scales, with scores reported from 0 to 100 (0 representing the best score). The LCSS subscore is the average symptom burden index computed as the mean score for all six major symptoms. Symptomatic progression was defined as a worsening in the average symptom burden index by 25%.
| months | A: NGR-hTNF + BIC | B: Placebo+BIC |
|---|---|---|
| Time to LCSS Symptomatic Progression | 3.2 (2.1 to 4.4) | 3.0 (2.8 to 3.4) |
Medical resource use data collected will be used in health economic analyses where it may be combined with other data from other sources such as cost data or other clinical parameters.
| Participants | A: NGR-hTNF + BIC | B: Placebo+BIC |
|---|---|---|
| ACE INHIBITORS, COMBINATIONS | 0 | 2 |
| ACE INHIBITORS, PLAIN | 5 | 2 |
| ADRENERGICS, INHALANTS | 7 | 10 |
| AMINOGLYCOSIDE ANTIBACTERIALS | 2 | 2 |
| ANESTHETICS, LOCAL | 0 | 4 |
| ANGIOTENSIN II ANTAGONISTS,COMBINATIONS | 1 | 4 |
| ANGIOTENSIN II ANTAGONISTS, plain | 2 | 5 |
| ANTACIDS | 7 | 3 |
| ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES | 13 | 7 |
| ANTIADRENERGIC AGENTS CENTRALLY ACTING | 0 | 2 |
| ANTIADRENERGIC AGENTS PERIPHERALLY ACTING | 0 | 2 |
| ANTIANDROGENS | 0 | 1 |
| ANTIARRHYTHMICS, CLASS I AND III | 4 | 3 |
| ANTIBIOTICS FOR TOPICAL USE | 0 | 4 |
| ANTIDEPRESSANTS | 17 | 2 |
| ANTIDIARRHEAL MICROORGANISMS | 2 | 1 |
| ANTIEMETICS AND ANTINAUSEANTS | 107 | 110 |
| ANTIEPILEPTICS | 3 | 2 |
| ANTIFIBRINOLYTICS | 1 | 0 |
| ANTIFUNGALS FOR TOPICAL USE | 2 | 0 |
| ANTIGLAUCOMA PREPARATIONS AND MIOTICS | 0 | 1 |
| ANTIGOUT PREPARATIONS | 10 | 12 |
| ANTIHISTAMINES FOR SYSTEMIC USE | 66 | 31 |
| ANTIINFECTIVES | 0 | 1 |
| ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COM | 0 | 2 |
| ANTIINFLAMMATORY ANANTIRHEUMATIC PRODUCTSD | 58 | 65 |
| ANTIMETABOLITES | 1 | 1 |
| ANTIMYCOTICS FOR SYSTEMIC USE | 15 | 14 |
| ANTIPROPULSIVES | 4 | 8 |
| ANTIPRURITICS | 3 | 2 |
| ANTIPSYCHOTICS | 7 | 3 |
| ANTITHROMBOTIC AGENTS | 41 | 42 |
| ANTIVERTIGO PREPARATIONS | 2 | 1 |
| ANXIOLYTICS | 24 | 16 |
| ASCORBIC ACID (VITAMIN C) | 0 | 1 |
| BACTERIAL VACCINES | 1 | 0 |
| BELLADONNA AND DERIVATIVES | 3 | 4 |
| BETA BLOCKING AGENTS AND OTHER ANTIHYPERTENSIVES | 11 | 15 |
| BETA-LACTAM ANTIBACTERIALS, PENICILLINS | 38 | 29 |
| BILE THERAPY | 1 | 1 |
| BLOOD AND RELATED PRODUCTS | 21 | 26 |
| BLOOD GLUCOSE LOWERING DRUGS EXCL. INSULINS | 2 | 6 |
| CALCIUM | 19 | 12 |
| CAPILLARY STABILIZING | 1 | 0 |
| CARDIAC GLYCOSIDES | 1 | 3 |
| CARDIAC STIMULANTS EXCL CARDIAC GLYCOSIDES | 1 | 0 |
| CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN | 138 | 108 |
| CORTICOSTEROIDS, PLAIN | 2 | 1 |
| COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS | 2 | 5 |
| COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPEC | 7 | 17 |
| DECONGESTANTS AND ANTIALLERGICS | 0 | 1 |
| DIRECT ACTING ANTIVIRALS | 2 | 2 |
| DIURETICS AND POTASSIUM-SPARING AGENTS | 6 | 3 |
| DRUGS AFFECTING BONE | 2 | 3 |
| DRUGS FOR CONSTIPATION | 39 | 63 |
| DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | 3 | 5 |
| DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REF | 74 | 71 |
| DRUGS FOR TREATMENT OF TUBERCULOSIS | 2 | 0 |
| DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY | 4 | 1 |
| ECTOPARASITICIDES, INC SCABICIDESL. | 0 | 1 |
| EMOLLIENTS AND PROTECTIVES | 1 | 0 |
| EXPECTORANTS EXCL COMBINATIONS WITH COUGH SUPPR. | 14 | 9 |
| HIGH-CEILING DIURETICS | 19 | 20 |
| HORMONES AND RELATED AGENTS | 0 | 1 |
| HYPNOTICS AND SEDATIVES | 14 | 14 |
| HYPOTHALAMIC HORMONES | 0 | 1 |
| I.V. SOLUTION ADDITIVES | 17 | 21 |
| I.V. SOLUTIONS | 6 | 10 |
| IMMUNOSTIMULANTS | 20 | 19 |
| INSULINS AND ANALOGUES | 5 | 0 |
| INTESTINAL ANTIINFECTIVES | 3 | 2 |
| IRON PREPARATIONS | 14 | 9 |
| LIPID MODIFYING AGENTS, PLAIN | 4 | 4 |
| LOW-CEILING DIURETICS, EXCL THIAZIDES | 1 | 0 |
| MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS | 8 | 14 |
| MULTIVITAMINS, COMBINATIONS | 1 | 4 |
| MULTIVITAMINS, PLAIN | 4 | 5 |
| MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS | 0 | 1 |
| MYDRIATICS AND CYCLOPLEGICS | 2 | 3 |
| OPIOIDS | 135 | 160 |
| OTHER ANALGESICS AND ANTIPYRETICSD | 105 | 93 |
| OTHER ANTIANEMIC PREPARATIONS | 20 | 20 |
| OTHER ANTIBACTERIALS | 4 | 5 |
| OTHER ANTIDIARRHEALS | 1 | 0 |
| OTHER ANTINEOPLASTIC AGENTS | 0 | 2 |
| OTHER BETA-LACTAM ANTIBACTERIALS | 8 | 9 |
| OTHER CARDIAC PREPARATIONS | 3 | 0 |
| OTHER DRUGS FOR ACID RELATED DISORDERS | 0 | 1 |
| OTHER DRUGS FOR OBSTRUCTIVE | 7 | 8 |
| OTHER MINERAL SUPPLEMENTS | 4 | 5 |
| OTHER NUTRIENTS | 4 | 7 |
| OTHER OPHTHALMOLOGICALS | 0 | 1 |
| OTHER PLAIN VITAMIN PREPARATIONS | 2 | 0 |
| OTHER RESPIRATORY SYSTEM PRODUCTS | 2 | 0 |
| OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEA | 3 | 1 |
| OTHER VITAMIN PRODUCTS, COMBINATIONS | 1 | 2 |
| PERIPHERAL VASODILATORS | 0 | 1 |
| POTASSIUM | 4 | 5 |
| POTASSIUM-SPARING AGENTS | 1 | 5 |
| PROPULSIVES | 68 | 87 |
| PSYCHOLEPTICS AND PSYCHOANALEPTICS | 0 | 1 |
| PSYCHOSTIMULANTS, | 0 | 1 |
| QUINOLONE ANTIBACTERIALS | 31 | 36 |
| SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VA | 1 | 6 |
| STOMATOLOGICAL PREPARATIONS | 20 | 19 |
| SULFONAMIDES AND TRIMETHOPRIM | 2 | 0 |
| TETRACYCLINES | 0 | 4 |
| THYROID PREPARATIONS | 2 | 0 |
| TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN | 1 | 2 |
| UROLOGICALS | 3 | 1 |
| VASODILATORS USED IN CARDIAC DISEASES | 0 | 2 |
| VIRAL VACCINES | 1 | 0 |
| VITAMIN A AND D | 0 | 5 |
| VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN | 0 | 3 |
| VITAMIN B12 AND FOLIC ACID | 7 | 11 |
| VITAMIN K AND OTHER HEMOSTATICS | 1 | 3 |
| SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CA | 3 | 4 |
Collected over Through study completation, an average of 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A: NGR-hTNF + BIC | 12/193 (6.2%) | 56/193 (29%) | 190/193 (98.4%) |
| B: Placebo+BIC | 13/193 (6.7%) | 54/193 (28%) | 185/193 (95.9%) |
| Event | A: NGR-hTNF + BIC | B: Placebo+BIC |
|---|---|---|
| Uncertain study medication dose deliveredInjury, poisoning and procedural complications | 4/193 | 9/193 |
| Condition aggravetedGeneral disorders | 4/193 | 5/193 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/193 | 1/193 |
| NeutropeniaBlood and lymphatic system disorders | 2/193 | 4/193 |
| DeathGeneral disorders | 3/193 | 2/193 |
| Chest painGeneral disorders | 3/193 | 3/193 |
| PneumoniaInfections and infestations | 0/193 | 3/193 |
| ChillsGeneral disorders | 2/193 | 0/193 |
| PyrexiaGeneral disorders | 2/193 | 2/193 |
| Drug infusion reactionInjury, poisoning and procedural complications | 2/193 | 0/193 |
| Event | A: NGR-hTNF + BIC | B: Placebo+BIC |
|---|---|---|
| ChillsGeneral disorders | 104/193 | 23/193 |
| FatigueGeneral disorders | 93/193 | 94/193 |
| PainGeneral disorders | 91/193 | 89/193 |
| DysponoeaRespiratory, thoracic and mediastinal disorders | 63/193 | 56/193 |
| NauseaGastrointestinal disorders | 61/193 | 62/193 |
| NeutropeniaBlood and lymphatic system disorders | 57/193 | 60/193 |
| Decreased appetiteMetabolism and nutrition disorders | 46/193 | 51/193 |
| PyrexiaGeneral disorders | 48/193 | 39/193 |
| CoughRespiratory, thoracic and mediastinal disorders | 39/193 | 47/193 |
| ConstipationGastrointestinal disorders | 42/193 | 45/193 |
Patients ≥ 18 years with advanced malignant pleural mesothelioma previously treated with a pemetrexed based chemotherapy regimen for advanced or metastatic disease.
| Age, Categorical(Participants) | A: NGR-hTNF + BIC | B: Placebo+BIC | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 92 | 87 | 179 |
| >=65 years | 108 | 113 | 221 |
| Age, Continuous(years) | A: NGR-hTNF + BIC | B: Placebo+BIC | Total |
|---|---|---|---|
| Median | 65 (25 to 89) | 67 (31 to 81) | 66 (25 to 89) |
| Sex: Female, Male(Participants) | A: NGR-hTNF + BIC | B: Placebo+BIC | Total |
|---|---|---|---|
| Female | 44 | 55 | 99 |
| Male | 156 | 145 | 301 |
| Race (NIH/OMB)(Participants) | A: NGR-hTNF + BIC | B: Placebo+BIC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 198 | 197 | 395 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Region of Enrollment(participants) | A: NGR-hTNF + BIC | B: Placebo+BIC | Total |
|---|---|---|---|
| Canada | 3 | 5 | 8 |
| Netherlands | 5 | 2 | 7 |
| Sweden | 1 | 1 | 2 |
| Belgium | 5 | 8 | 13 |
| United States | 14 | 12 | 26 |
| Ireland | 3 | 1 | 4 |
| Egypt | 17 | 19 | 36 |
| Poland | 17 | 14 | 31 |
| Italy | 79 | 84 | 163 |
| United Kingdom | 49 | 46 | 95 |
| France | 4 | 6 | 10 |
| Spain | 3 | 2 | 5 |
Ran from Apr 2010 to primary completion in Apr 2014, 48 months.
Results were first posted in Sep 2019, 5 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AGC Biologics S.p.A.